Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
- PMID: 14563637
- DOI: 10.1182/blood-2003-07-2548
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
Abstract
In follicular lymphoma (FL), genomic polymorphisms corresponding to the expression of valine (V) or phenylalanine (F) at amino acid 158 of Fc gamma RIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been associated with varied responses to rituximab. We examined Fc gamma RIIIa polymorphisms of 30 CLL patients with the phenotypes V/V (n = 6), V/F (n = 12), and F/F (n = 12) treated with thrice-weekly rituximab (375 mg/m(2)) for 4 weeks to correlate polymorphism type with infusion toxicity and response. Infusion toxicity (grade 3 or greater or hypoxia/hypotension requiring transient cessation of therapy) was observed equally among the groups (V/V, 50%; V/F, 33%; F/F, 41.6%; P =.78). The response to rituximab was also similar among the different polymorphism phenotypes (V/V, 33%; V/F, 41.6%; F/F, 50%). These data suggest that Fc gamma RIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important.
Similar articles
-
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.Clin Lymphoma Myeloma. 2007 Jan;7(4):286-90. doi: 10.3816/clm.2007.n.004. Clin Lymphoma Myeloma. 2007. PMID: 17324336
-
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.J Clin Oncol. 2003 Nov 1;21(21):3940-7. doi: 10.1200/JCO.2003.05.013. Epub 2003 Sep 15. J Clin Oncol. 2003. PMID: 12975461
-
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17. J Clin Oncol. 2008. PMID: 18347005
-
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Expert Rev Anticancer Ther. 2010. PMID: 20942624 Review.
-
Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):347-52. doi: 10.3816/CLML.2010.n.067. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21030347 Review.
Cited by
-
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Blood. 2010 Nov 11;116(19):3705-14. doi: 10.1182/blood-2010-04-001230. Epub 2010 Jul 7. Blood. 2010. PMID: 20610811 Free PMC article. Review.
-
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.Br J Cancer. 2009 Jan 13;100(1):113-7. doi: 10.1038/sj.bjc.6604812. Epub 2008 Dec 9. Br J Cancer. 2009. PMID: 19066610 Free PMC article.
-
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma.Clin Cancer Res. 2019 Aug 15;25(16):4955-4965. doi: 10.1158/1078-0432.CCR-18-2108. Epub 2019 May 29. Clin Cancer Res. 2019. PMID: 31142501 Free PMC article. Clinical Trial.
-
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.PLoS One. 2011;6(6):e21018. doi: 10.1371/journal.pone.0021018. Epub 2011 Jun 15. PLoS One. 2011. PMID: 21698301 Free PMC article.
-
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Immunol Cell Biol. 2017 Apr;95(4):347-355. doi: 10.1038/icb.2017.6. Epub 2017 Feb 21. Immunol Cell Biol. 2017. PMID: 28138156 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources